• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Stock

US prosecutors drop fentanyl trafficking charges against Indian pharma executive

by September 12, 2025
by September 12, 2025

US prosecutors have moved to dismiss charges of alleged fentanyl trafficking against an Indian pharmaceutical executive, marking a rare reversal in Washington’s intensifying campaign against the global supply chain of synthetic opioids.

The decision shifts attention back to India’s role in the trade, after recent intelligence reports identified the country as a growing supplier of precursor chemicals used in illicit fentanyl production.

The development also highlights the challenges faced by authorities in proving cases against individuals and companies operating in a complex international pharmaceutical market, where regulatory approvals and legitimate trade coexist with allegations of illegal diversion.

Case against Vasudha executive dismissed

On Thursday, prosecutors in Washington asked a federal judge to dismiss charges against Venkata Naga Madhusudhan Raju Manthena, marketing director at Hyderabad-based Vasudha Pharma Chem Ltd.

Manthena was indicted in March alongside the company and two other executives, accused of conspiring to distribute chemicals that could be used to manufacture fentanyl.

The court filing stated prosecutors had “learned additional information that has changed the Government’s view” of the evidence against him.

The charges against the other two Vasudha executives remain in place, as does the indictment against the company. Neither the firm nor its leadership in India face charges within the country.

India’s growing scrutiny in the fentanyl trade

The move comes as India faces increasing scrutiny from US authorities in the global fight against fentanyl, which has fuelled a public health crisis in America.

While enforcement has historically focused on Canada, Mexico, and China, a US intelligence report in March identified India as the world’s second-largest supplier of illicit fentanyl precursor chemicals and pill-pressing equipment, after China.

The indictment of Vasudha Pharma in March made it the most prominent Indian pharmaceutical firm to be pulled into the US crackdown. Vasudha manufactures active pharmaceutical ingredients and drug intermediates, supplying both domestic and global clients.

The company holds regulatory approvals from the US Food and Drug Administration and reported revenues of more than 11.5 billion rupees ($130 million) in the fiscal year ending March 2024, according to India Ratings and Research.

US prosecutors have also taken action against other Indian companies this year. In January, Athos Chemicals Pvt. and Raxuter Chemicals, both based in Gujarat, were indicted on fentanyl-related charges.

Raxuter’s founder, Bhavesh Lathiya, was arrested and has pleaded not guilty. Athos has not entered a plea and has not responded publicly.

Wider context of US trade and enforcement

India’s involvement in the fentanyl crackdown intersects with broader trade tensions. Former US President Donald Trump imposed tariffs on India, alongside Canada, Mexico, and China, accusing these nations of failing to do enough to stem the fentanyl supply chain.

India was already a focus of US tariffs over its purchases of discounted Russian oil, further complicating the trade relationship.

The Vasudha case illustrates the complexity of prosecuting companies with dual identities — operating legally within regulated pharmaceutical markets while facing allegations of facilitating illegal drug production.

The dismissal of charges against Manthena underscores these challenges and leaves the wider case against Vasudha and its executives ongoing.

Ongoing cases highlight enforcement challenges

The Department of Justice’s pursuit of Indian companies is part of a broader effort to target upstream suppliers in the fentanyl trade.

The arrest of Raxuter’s founder in January shows that prosecutions can advance, but the dismissal of charges against Vasudha’s executive demonstrates the difficulties of gathering sufficient evidence in cross-border cases.

No timeline has been given for the next steps in the Vasudha case, and US prosecutors have not indicated whether further indictments against Indian firms may follow.

For now, the spotlight remains on India as it emerges as a critical player in the supply chain of precursor chemicals at the centre of the global fentanyl crisis.

The post US prosecutors drop fentanyl trafficking charges against Indian pharma executive appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Pastor recalls last moments with Charlie Kirk: ‘American martyr’
next post
SK Hynix to mass produce HBM4 chips as Nvidia demand fuels record gains

Related Posts

Cyberattack halts Asahi production, disrupts Japan’s beer supply

October 3, 2025

Europe markets open: Stoxx 600 rises 0.4%, extending...

October 3, 2025

Bitcoin ETFs see over $600M in inflows as...

October 3, 2025

Stockholm leads Europe in IPO activity with $6.8...

October 3, 2025

Indonesia suspends TikTok licence after data refusal during...

October 3, 2025

Why the Thai baht’s climb against US dollar...

October 3, 2025

OpenAI valuation hits $500 billion as employees sell...

October 2, 2025

Here’s why JPMorgan, Morningstar are bullish on Alibaba...

October 2, 2025

Europe markets open: Stoxx 600 jumps 0.6%, led...

October 2, 2025

Will the Tesco share price hit 500p as...

October 2, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • What I Saw in Milei’s Argentina

    October 3, 2025
  • Tariffs Rest on Distrust of Citizens

    October 3, 2025
  • Cyberattack halts Asahi production, disrupts Japan’s beer supply

    October 3, 2025
  • Europe markets open: Stoxx 600 rises 0.4%, extending its record-setting rally

    October 3, 2025
  • Bitcoin ETFs see over $600M in inflows as BTC price nears $120K

    October 3, 2025
  • Stockholm leads Europe in IPO activity with $6.8 billion raised

    October 3, 2025

Editors’ Picks

  • 1

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 2

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • 3

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 4

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025
  • 5

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 6

    Nvidia’s investment in SoundHound wasn’t all that significant after all

    March 1, 2025
  • 7

    Pop Mart reports 188% profit surge, plans aggressive global expansion

    March 26, 2025

Categories

  • Economy (2,770)
  • Editor's Pick (279)
  • Investing (185)
  • Stock (1,885)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

Nikkei 225 index outlook ahead of BoJ...

March 18, 2025

Reliance AGM: Mukesh Ambani confirms Jio IPO...

August 29, 2025

Intel delays Ohio chip plant to 2030...

October 1, 2025